Abstract
The gene encoding Melanoma-differentiation antigen-7 (MDA-7) was discovered more than 10 years ago. Its potential anti-cancer activity was surmised because its expression is inversely correlated with the cell proliferation status. Indeed adenoviral delivery of this gene proved to be efficient in killing several cancer cell lines and great strides have been made concerning its molecular ways of action. Later it was shown that mda7 encoded a secreted cytokine which belongs to the IL-10, class-II family of cytokines. We recently found that this molecule exerted apoptotic activity on stimulating but not on resting lymphocytes from a B cell leukaemia. This activity is distinct from that of intracellular MDA-7, and may pave the way for using the cytokine in cancers provided that they express the IL-24 Receptors; in this respect, melanomas are insensitive to the recombinant cytokine due to the lack of IL-24 receptors at their surface. In contrast to its anti-cancer activity, the immunological role of IL-24 is still unclear, with differences between mice and human. If however it is demonstrated that IL-24 can inhibit the function of STAT3 in normal lymphocytes as it is the case in leukemic cells, and given that STAT3 is needed for the differentiation of several lymphocyte subsets, this will give us hints as to the potential role of this cytokine in the immune system.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Interleukin-24: A Molecule with Potential Anti-Cancer Activity and a Cytokine in Search of a Function
Volume: 9 Issue: 4
Author(s): Ali Dalloul and Alexander Sainz-Perez
Affiliation:
Abstract: The gene encoding Melanoma-differentiation antigen-7 (MDA-7) was discovered more than 10 years ago. Its potential anti-cancer activity was surmised because its expression is inversely correlated with the cell proliferation status. Indeed adenoviral delivery of this gene proved to be efficient in killing several cancer cell lines and great strides have been made concerning its molecular ways of action. Later it was shown that mda7 encoded a secreted cytokine which belongs to the IL-10, class-II family of cytokines. We recently found that this molecule exerted apoptotic activity on stimulating but not on resting lymphocytes from a B cell leukaemia. This activity is distinct from that of intracellular MDA-7, and may pave the way for using the cytokine in cancers provided that they express the IL-24 Receptors; in this respect, melanomas are insensitive to the recombinant cytokine due to the lack of IL-24 receptors at their surface. In contrast to its anti-cancer activity, the immunological role of IL-24 is still unclear, with differences between mice and human. If however it is demonstrated that IL-24 can inhibit the function of STAT3 in normal lymphocytes as it is the case in leukemic cells, and given that STAT3 is needed for the differentiation of several lymphocyte subsets, this will give us hints as to the potential role of this cytokine in the immune system.
Export Options
About this article
Cite this article as:
Dalloul Ali and Sainz-Perez Alexander, Interleukin-24: A Molecule with Potential Anti-Cancer Activity and a Cytokine in Search of a Function, Endocrine, Metabolic & Immune Disorders - Drug Targets 2009; 9 (4) . https://dx.doi.org/10.2174/187153009789839200
DOI https://dx.doi.org/10.2174/187153009789839200 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Classical to Current Approach for Treatment of Psoriasis: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets The Blood-Brain Barrier in Multiple Sclerosis: microRNAs as Key Regulators
CNS & Neurological Disorders - Drug Targets Proteomics Annotation of Lipid Rafts Modified by Virus Infection
Combinatorial Chemistry & High Throughput Screening Insights into the Structural Features Essential for JAK2 Inhibition and Selectivity
Current Medicinal Chemistry α-Halogenoacrylic Derivatives of Antitumor Agents
Mini-Reviews in Medicinal Chemistry Cellular Therapy of Lysosomal Storage Disorders: Current Status and Future Prospects
Current Pediatric Reviews Fragment-Based Discovery of Inhibitors of Protein Kinase B
Current Topics in Medicinal Chemistry Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology
Recent Patents on Anti-Cancer Drug Discovery Adenosine Deaminase in the Modulation of Immune System and its Potential as a Novel Target for Treatment of Inflammatory Disorders
Current Drug Targets HIV-1 Vpr: A Closer Look at the Multifunctional Protein from the Structural Perspective
Current HIV Research MicroRNAs in Leukemias: Emerging Diagnostic Tools and Therapeutic Targets
Current Drug Targets The Novel Role for Lyn in Integrin Signaling in Human Disease
Current Signal Transduction Therapy Some Implications of Receptor Kinase Signaling Pathway for Development of Multitargeted Kinase Inhibitors
Current Radiopharmaceuticals Application of Mesenchymal Stem Cells in Melanoma: A Potential Therapeutic Strategy for Delivery of Targeted Agents
Current Medicinal Chemistry Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Plants vs. Cancer: A Review on Natural Phytochemicals in Preventing and Treating Cancers and Their Druggability
Anti-Cancer Agents in Medicinal Chemistry Irinotecan for Treatment of Childhood Cancers: A Promising Therapeutic Partner
Current Cancer Therapy Reviews Nuclear Magnetic Resonance Spectroscopy of Lipids in Cancer
Current Organic Chemistry Pluripotent Stem Cells for Livestock Health and Production
Current Stem Cell Research & Therapy Oral and Dental Considerations in the Management of Leukemic Children
Applied Clinical Research, Clinical Trials and Regulatory Affairs